Over-the-Counter Medicines
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Gain critical insights into global OTC drug markets, regulatory shifts, and competitive landscapes for pharma BD and investment strategies.
Showing 1–3 of 3 articles
Quick answer
NovaPharmaNews Over-the-Counter Medicines hub for FDA covers 3 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
FDA approves OTC Rextovy, broadening naloxone access for opioid overdose
Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
FDA Approves First OTC Naloxone Nasal Spray for Opioid Overdose
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.